In yesterday’s Wall Street session, ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares traded at $0.78, up 10.87% from the previous session.
As of this writing, 2 analysts cover ASLAN Pharmaceuticals Limited (NASDAQ:ASLN). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $7.00 and a low of $4.00, we find $5.50. Given the previous closing price of $0.70, this indicates a potential upside of 685.71 percent. ASLN stock price is now 48.44% away from the 50-day moving average and 38.96% away from the 200-day moving average. The market capitalization of the company currently stands at $54.94M.
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $5.50 as their price target over the next twelve months.
With the price target of $8, Jefferies recently initiated with Buy rating for ASLAN Pharmaceuticals Limited (NASDAQ: ASLN). On January 14, 2019, H.C. Wainwright reiterated its ‘Buy’ rating on the stock by increasing its target price from $12 to quote $8.50.
A total of 0.05% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ASLN stock. A new stake in ASLAN Pharmaceuticals Limited shares was purchased by CAPITAL ANALYSTS, LLC during the first quarter worth $8,000. ROYAL BANK OF CANADA invested $3,000 in shares of ASLN during the first quarter. In the first quarter, UBS GROUP AG acquired a new stake in ASLAN Pharmaceuticals Limited valued at approximately $1,000. In total, there are 29 active investors with 31.60% ownership of the company’s stock.
Tuesday morning saw ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) opened at $0.7400. During the past 12 months, ASLAN Pharmaceuticals Limited has had a low of $0.34 and a high of $1.16. As of last week, the company has a debt-to-equity ratio of 0.81, a current ratio of 9.60, and a quick ratio of 9.60. The fifty day moving average price for ASLN is $0.5255 and a two-hundred day moving average price translates $0.5614 for the stock.
The latest earnings results from ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.19, missing analysts’ expectations of -$0.12 by -0.07. This compares to -$0.12 EPS in the same period last year. The company reported revenue of $10.29 million for the quarter, compared to $8.03 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 28.21 percent.
ASLAN Pharmaceuticals Limited(ASLN) Company Profile
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company’s clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.